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Protein stabilityResearch into the mechanisms by which proteins fold into their native structures has been on-going since
the work of Anﬁnsen in the 1960s. Since that time, the folding mechanisms of small, water-soluble pro-
teins have been well characterised. By contrast, progress in understanding the biogenesis and folding
mechanisms of integral membrane proteins has lagged signiﬁcantly because of the need to create a mem-
brane mimetic environment for folding studies in vitro and the difﬁculties in ﬁnding suitable conditions
in which reversible folding can be achieved. Improved knowledge of the factors that promote membrane
protein folding and disfavour aggregation now allows studies of folding into lipid bilayers in vitro to be
performed. Consequently, mechanistic details and structural information about membrane protein fold-
ing are now emerging at an ever increasing pace. Using the panoply of methods developed for studies of
the folding of water-soluble proteins. This review summarises current knowledge of the mechanisms of
outer membrane protein biogenesis and folding into lipid bilayers in vivo and in vitro and discusses the
experimental techniques utilised to gain this information. The emerging knowledge is beginning to allow
comparisons to be made between the folding of membrane proteins with current understanding of the
mechanisms of folding of water-soluble proteins.
 2014 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/3.0/).Principles of protein folding
How water-soluble proteins fold
The biological activity of many proteins is reliant on their ability
to adopt a speciﬁc, three-dimensional structure. Failure to achieve
this structure can have serious consequences, as evidenced by the
prevalence of diseases caused by protein misfolding and aggrega-
tion [1,2]. The information required for a polypeptide chain to at-
tain its native structure was shown to be contained within its
primary sequence by Anﬁnsen’s experiments on ribonuclease A
[3,4]. This small, globular protein was completely unfolded in
chemical denaturants and shown to regain its native conformation
spontaneously upon dialysis [3]. This seemingly simple conclusion
has led to decades of scientiﬁc research to determine how the ami-
no acid sequence of a protein confers its native structure.
If folding were to occur by random sampling of all possible
conformations of the polypeptide chain, ﬁnding the native state
would take an astronomically long time. Proteins, however, foldon biologically relevant timescales [5]. Levinthal suggested that
this apparent paradox could be resolved if proteins fold via deﬁned
pathways [6]. Following this conclusion, several mechanisms were
proposed to describe the pathways traversed by a protein en route
to the native state. Analysis of the refolding kinetics of ribonucle-
ase A revealed two distinct phases [7] and led to the suggestion
of a ‘‘framework’’ mechanism of folding whereby secondary struc-
tural elements of proteins are formed prior to their docking to form
the tertiary structure [8–10]. Further investigation of the refolding
of ribonuclease A revealed that one of the phases observed was not,
in fact, due to the presence of an observable folding intermediate,
but arose as a consequence of proline cis–trans isomerisation [11].
This realisation, alongside the characterisation of the folding of
chymotrypsin inhibitor 2 which revealed a simple two-state fold-
ing mechanism [12–14], saw the framework mechanism become
disfavoured due to its implication that folding intermediates
should be present [10,15]. To explain folding in the absence of
detectable intermediates, the nucleation-condensation mechanism
was proposed by Fersht and co-workers [12]. This mechanism
involves the formation of a small nucleus of structure stabilised
by weak, possibly long-range, contacts and the subsequent rapid
collapse around this folding nucleus to yield the native state
[10,12,15]. A combination of simulation and experimental data
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vealed that the seemingly contrasting framework and nucleation-
condensation folding models could be considered as two extremes
of a single mechanism. In this uniﬁed model, the relative stability
of the secondary and tertiary structure determines whether these
elements are formed in series or in parallel [16] and, thus, two dec-
ades of conﬂicting evidence were resolved.
More recently it has been realised that proteins fold via a collec-
tion of parallel pathways which make up a funnel-shaped energy
landscape (Fig. 1) [17–20]. At the top of the funnel, the unfolded
state represents a large ensemble of high-entropy conformations
of the polypeptide chain. While unstructured, the polypeptide
chain may be biased by weak, residual interactions which initiate
folding [21]. Indeed, an unfolded variant of the bacterial immunity
protein Im7 has been studied recently under non-denaturing
conditions, revealing conformational restriction in the regions of
the protein sequence which ultimately form the native helices,
emphasising the importance of such interactions in the initiation
of folding [22]. Similar conclusions have been drawn from other
proteins and protein fragments under different denaturing condi-
tions [23–28]. As folding progresses, the polypeptide chain under-
goes many reorganisations aiding the formation of stabilising
interactions between side-chains, the protein backbone and the
solvent as the protein approaches the native state [17]. The land-
scape view is an attractive one as it does not place restrictionsFig. 1. Schematic representation of funnel-shaped folding landscapes. Example of
(a) a smooth folding landscape expected for a two-state folding mechanism where
only the native and unfolded states are stably populated and (b) a rugged landscape
wherein the polypeptide chain populates one or more intermediate structures
which represent local energy minima. Reprinted from [31] by permission from
Macmillan Publishers Ltd: Nat. Struct. Mol. Biol.  2009.on whether secondary structure must form before, or at the same
time, as the tertiary structure. Additionally, the funnel-shaped
landscape predicts the experimentally observed robustness of the
folding process to destabilising mutations: if the ﬁnal fold remains
the most stable state relative to the unfolded ensemble, a mutation
may block some of the pathways to the native state but alternative
folding pathways can be utilised [17].
The landscape theory of protein folding also predicts the exis-
tence of ‘‘downhill folding’’, that is, folding in the absence of signif-
icant energy barriers [17]. Even with the most powerful single
molecule techniques available it is still difﬁcult to experimentally
identify barrier-less folding unequivocally [29]. Exciting develop-
ments in simulation methods have recently enabled the ﬁrst
visions of protein folding in all-atom detail for small, single domain
proteins [30]. These simulations have suggested that at least 9 of
the 12 rapidly-folding proteins studied experience energy barriers
that slow folding [30]. For proteins in which only the native and
unfolded states are stably populated, known as a two-state folding
mechanism, the folding energy landscape is relatively smooth
(Fig. 1a) [31]. With the advent of more rapid triggering methods
(ultra-rapid mixing, temperature jump, etc. [31]) and more sensi-
tive detection methods (e.g. single molecule techniques [32–34]),
such a simple folding scenario is rarely observed, even for small
proteins. Instead, the folding landscape is often rugged with local
energy minima representing the population of one or more folding
intermediates en route to the native state (Fig. 1b) [31,35].
Rugged folding landscapes result as a consequence of the need
to form the thousands of weak, stabilising interactions which are
present in the native state (reviewed in Ref. [31]). During the struc-
tural reorganisations that are required for the protein to traverse
the folding landscape, it is not always possible to minimise the en-
ergy of all of these interactions simultaneously, leading to ‘‘frustra-
tion’’ in the landscape [19,36]. Theory predicts that a rough
landscape will lead to slower folding by limiting the rate at which
the protein can ﬁnd the native state [19]. Recently the effect of sol-
vent viscosity on the folding and unfolding kinetics of homologous
domains of a-spectrin was studied, revealing the ﬁrst explicit
experimental evidence that differences in internal friction, and
hence frustration, can indeed inﬂuence the folding kinetics of
structurally homologous proteins [37]. It has been suggested previ-
ously that frustration, and hence ruggedness of energy landscapes,
arises due to conﬂicting pressures to evolve protein sequences
which can reliably fold to a stable native structure and that are
capable of carrying out a deﬁned biological role [19,36]. While this
may be the case for some proteins, the differences in unfolding
rates of structurally and functionally similar a-spectrin domains
were shown to be a consequence of different degrees of landscape
ruggedness, with slower unfolding occurring as a result of in-
creased frustration [37]. This result suggests that frustration has
been selected to slow unfolding in this protein domain, which
has an unusually long half-life in vivo [37]. Folding of the Trp-cage
mini protein was also shown to be slowed when its folding inter-
mediate was destabilised by the presence of chemical denaturant
or a helix-breaking mutation [38]. This suggests that local ener-
getic minima in the folding landscape can act to separate the con-
formational search into multiple, smaller problems and hence
accelerate the conformational search process (reviewed in Ref.
[35]). Whether folding intermediates act to disrupt or promote
the folding process for many proteins is still under debate. The util-
ity of intermediate species in providing insights into the structural
regulation of biological function as well as their role in the initia-
tion of protein aggregation and recognition by molecular chaper-
ones, makes them important targets of study [39].
This brief overview of the folding of small water-soluble pro-
teins has outlined how modern advances in experimental and
computational techniques have provided signiﬁcant progress
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this class of proteins. Many fundamental questions remain unan-
swered about this complex and important biological process, par-
ticularly regarding the folding of more complicated systems such
as multi-domain proteins, folding in the cellular milieu and mem-
brane protein folding [40–44]. Current research into understanding
the latter problem, focussing on bacterial outer membrane proteins
(OMPs), is covered in the following sections.The membrane protein folding problem
Understanding the folding, stability and function of membrane
proteins is an important area of research as these proteins repre-
sent 60% of current drug targets and have vital roles in the cell,
including signalling, transport and biogenesis [45,46]. In contrast
with the wealth of information available about the folding of small,
water-soluble proteins, the ﬁeld of membrane protein folding hasFig. 2. Example structures of integral membrane proteins. Structures of (a) the
transmembrane segment of a glycophorin A monomer from human erythrocyte
membranes solved by NMR spectroscopy (1AFO [228]); (b) bacteriorhodopsin, a
seven-helical bundle from the purple membrane of Halobacterium salinarum (1C3W
[229]); (c) calcium ATPase 1 from the sarcoplasmic reticulum membrane of
Oryctolagus cuniculus, a ten-helical bundle with a large cytoplasmic domain (1IWO
[230]); (d) PagP, an 8-stranded palmitoyl transferase enzyme from E. coli (1THQ
[206]); (e) the 8-stranded transmembrane domain of OmpA, an ion channel from
E. coli (1BXW [231]), with the C-terminal periplasmic domain (structure currently
not determined) represented by a red circle; (f) the 10-stranded OM protease,
OmpT, from E. coli (1I78 [232]); (g) the 12-stranded, colicin-secreting phospholi-
pase A, OmpLA, from E. coli (1QD5 [233]); (h) the OmpF porin, a trimer comprised of
three 16-stranded b-barrels, from E. coli (2ZFG [234]) and (i) the 24-stranded
translocation domain of PapC from E. coli (3FIP [235]). Unless otherwise speciﬁed,
all structures were solved using X-ray crystallography. Proteins are coloured
rainbow: violet (N-terminus) to red (C-terminus). In (h), a single OmpF monomer is
coloured, while the remaining monomers are shown in greyscale. The approximate
position of the membrane is indicated in all images with grey shading. All images
were generated from the PDB ﬁles using the accession numbers given in brackets
using UCSF Chimera molecular visualisation application [236].lagged signiﬁcantly [47]. For water-soluble proteins, folding is
driven by the need to bury hydrophobic side-chains in order to
prevent aggregation and to facilitate the formation of stable
structures [40]. In addition to the attainment of the native state,
the folding of integral membrane proteins is complicated by the
need to insert the polypeptide chain into a lipid membrane [47].
Following membrane insertion, most of the surface of an integral
membrane protein is in contact with the membrane’s hydrophobic
interior. Hydrophilic residues are either restricted to regions which
contact the polar head groups of the membrane lipids or are ex-
posed to the aqueous environment on either side of the membrane
[47]. Additionally, the membrane environment in vivo is highly
dynamic and heterogeneous with regions of varying lipid composi-
tion [48]. Recreating this environment in vitro has proved more
difﬁcult than the simple aqueous environment needed to fold
water-soluble proteins and this, in part, has limited studies on
the folding of integral membrane proteins [47,48].Classes of membrane proteins
The proteins present in biological membranes can be catego-
rised into two families: the lipid-anchored proteins, which have a
covalently-bound fatty-acid moiety through which a water-soluble
protein is attached to a membrane, and the integral membrane
proteins, which contain membrane-spanning regions. Only the
folding mechanism of the latter will be described here. In contrast
with lipid-associated proteins, the integral membrane proteins are
constrained by the need to compensate for the energetic cost of
burying peptide bonds in the lipid bilayer [49], estimated to be
1.2 kcal/mol per peptide bond [50]. As a consequence, it was
predicted that membrane spanning regions would form regular
secondary structural elements in order to maximise the hydrogen
bonding potential of the peptide backbone [49]. Formation of
secondary structure reduces the energetic cost of incorporation
of peptide bonds into a bilayer by 0.4 kcal/mol per peptide bond
for a-helical structure and 0.5 kcal/mol per peptide bond for
b-sheet structure [50]. The ﬁrst a-helical membrane protein struc-
ture was solved in 1975 by Henderson and Unwin using electron
microscopy to generate a three-dimensional image of the purple
membrane of Halobacterium salinarum [51]. The resulting 7 Å reso-
lution image revealed the structure of bacteriorhodopsin (bR)1 to
be a seven helical, transmembrane bundle [51]. The structural infor-
mation available about bR has since been increased by structures at
higher resolution obtained using electron microscopy (3 Å, [52]) and
X-ray diffraction (1.43 Å, [53]). Since the structural elucidation of bR,
a wide variety of helical transmembrane structures have been solved
and deposited in the Protein Data Bank (PDB) [54]. These show a di-
verse range of size and function across the kingdoms of life. Some
examples are depicted in Fig. 2a–c.
In contrast with the ubiquitous distribution of a-helical
transmembrane proteins, membrane proteins containing b-sheet
secondary structure are found only in the outer membranes of
Gram-negative bacteria, mitochondria and chloroplasts [55,56].1 Abbreviations used: bR, bacteriorhodopsin; PDB, protein data bank; hVDAC,
human mitochondrial voltage-dependent anion-selective channel; NMR, nuclear
magnetic resonance; IM, inner membrane; OM, outer membrane; PE, phosphatidyl-
ethanolamine; PG, phosphatidylglycerol; LPS, lipopolysaccharide; OMP, outer mem-
brane protein; PPIase, parvulin-like peptidyl-prolyl isomerase; BAM, b-barrel
assembly machinery; MD, molecular dynamics; POTRA, polypeptide transport-
associated; CD, circular dichroism; SUV, small unilamellar vesicle; LUV, large
unilamellar vesicle; Cx:yPZ, a phospholipid where x indicates the number of carbon
atoms in the acyl chain, y indicates the number of double bonds per acyl chain and Z
represents the head-group moiety; PC, phosphatidylcholine; LDAO, N-lauryl-N,N-
dimethylammonium-N-oxide; HT PagP, C-terminally His-tagged PagP; SDS–PAGE,
sodium dodecyl sulphate polyacrylamide gel electrophoresis; GuHCl, guanidine
hydrochloride.
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backbone, each b-strand associates laterally with its neighbours
resulting in an overall cylindrical topology, known as a b-barrel
[55]. With predominantly non-polar side chains exposed to the
hydrophobic membrane interior and each of the backbone
hydrogen bonds satisﬁed, the resulting b-barrel structures have
high thermodynamic stability [50,57]. The size of the b-barrel is
highly variable, with known structures containing between 8 and
24 b-strands, and the proteins may contain periplasmic or extracel-
lular domains [55,56]. The regions between b-strands often
alternate between tight turns on the periplasmic side of the mem-
brane and longer, more ﬂexible loops on the outer surface, which
are exposed to the external environment (Fig. 2d–i) [55]. One al-
most entirely conserved structural feature across this family of
protein structures is an even number of b-strands, with only one
known exception to this rule discovered thus far: the 19-stranded
human mitochondrial voltage-dependent anion-selective channel
(hVDAC) [56,58].
As more and more research is focused on the determination of
membrane protein structure, a total of over 430 unique structures
have now been reported in the membrane protein structure
(mpstruc) database with both a-helical and b-barrel proteins rep-
resented [59]. Structure determination has been most successful
using X-ray diffraction, although 105 of the reported structures
were solved using nuclear magnetic resonance (NMR) spectros-
copy and a further 14 structures have been solved using electron
diffraction, demonstrating the utility of multiple techniques in
the membrane protein structure determination tool box [60,61].
Almost 30 years after the ﬁrst structure was reported, integral
membrane proteins still account for only 1% of the protein struc-
tures in the PDB [62]. Signiﬁcant progress is being made in this
area, however, with 64 structures determined in 2012 and 50 in
2013 to date [59].Biological membranes
Lipids in cells have three main functions: energy storage, signal
transduction and forming the matrix of biological membranes –
the approximately 30 Å thick layer which encloses the cell and
organelles within eukaryotic cells [63]. Cellular membranes are
composed of polar lipids, which self-associate into bilayers to
shield the hydrophobic regions from the aqueous environment in
a process driven entropically by water molecules [63]. The struc-
ture and composition of lipid bilayers varies greatly even within
an organism, allowing the properties of different membranes to
be tailored to a speciﬁc function. Modulation of lipid composition
to adapt to different functional requirements implies the evolu-
tionary advantage of an extensive and complex lipid repertoire
[63]. In addition to varying lipid composition, membranes can have
either a symmetrical or asymmetrical distribution of lipids be-
tween the two leaﬂets of the bilayer. Within a leaﬂet, favourable
interactions between some of the lipid components can generate
domains of speciﬁc lipid composition, known as lipid rafts, which
are thought to be involved in localising membrane proteins [63].
The variable properties of biological membranes demonstrate the
highly dynamic, heterogeneous and complex nature of the lipid
environment in which integral membrane proteins must insert,
fold and function.The cell envelope of Gram-negative bacteria
A hallmark of Gram-negative bacteria, such as Escherichia coli, is
the cell envelope, which is composed of two lipid membranes
enclosing an aqueous compartment called the periplasm (Fig. 3a)
[64,65]. The inner membrane (IM) is a symmetric phospholipidbilayer composed of approximately 70% phosphatidylethanol-
amine (PE, Fig. 3d), 25% phosphatidylglycerol (PG, Fig. 3e) and 5%
or less cardiolipin (Fig. 3f) and forms the barrier between the cyto-
plasm and the periplasm (Fig. 3a) [64–66]. There are two types of
protein associated with the IM; lipoproteins which undergo lipid
modiﬁcations of an N-terminal cysteine residue to anchor them
to the periplasmic face of the IM and the a-helical integral mem-
brane proteins (reviewed in Ref. [65]). IM proteins are responsible
for many cellular processes, including lipid synthesis and small
molecule transport. This class of proteins is discussed at length
elsewhere in this issue.
The periplasm is the compartment between the IM and the out-
er membrane (OM), which comprises around 10% of the total cell
volume and contains soluble proteins, as well as a peptidoglycan
cell wall. The peptidoglycan layer plays important roles in main-
taining the shape of the cell and preventing lysis, while periplasmic
proteins are involved in maintaining the integrity of the cell enve-
lope. The processes which take place in the periplasm are indepen-
dent of nucleotide hydrolysis, since no ATP is present in this
compartment [65,67]. When energy is required, the cell relies on
complex coupling mechanisms which often use the proton-motive
force across the inner membrane as the primary energy source
[65].
The inner leaﬂet of the asymmetric OM is comprised of phos-
pholipids and is similar in composition to the IM, although the
PE content is enriched compared with the IM (Fig. 3b) [65,66].
The outer leaﬂet of the OM consists of lipopolysaccharide (LPS), a
glycolipid typically consisting of lipid A, a core oligosaccharide
and an O-antigen (Fig. 3c) [64,68]. The structure of the O-antigen
is highly variable, even within a species, with approximately 170
variants being recorded in E. coli [69]. The high number of fatty
acid chains on LPS compared with phospholipids, and the fact that
these chains are saturated, facilitates tight packing of the LPS mol-
ecules in the OM [68]. This confers low ﬂuidity to the membrane
and it is this property that is responsible for the low permeability
of the OM [68]. As a consequence, rapid diffusion of small, hydro-
phobic molecules across the OM is prevented and Gram-negative
bacteria thus tend to be less susceptible to hydrophobic antibiotics
than their Gram-positive counterparts [68]. As with the IM, inte-
gral membrane proteins and lipoproteins are associated with the
OM, but in this membrane the integral outer membrane proteins
(OMPs) usually have b-barrel structures [55,65]. The barrel is
formed by membrane-spanning b-strands which are held together
by a lateral hydrogen bond network [55]. One reported exception,
the polysaccharide translocon Wza of E. coli, has a barrel structure
composed of laterally associated a-helices [70]. Several examples
of OMP structures are shown in Fig. 2d–i.
OMP biogenesis in vivo
Periplasmic chaperones assisting OMP biogenesis
Following their synthesis in the cytosol, OMPs are targeted to
the SecYEG translocon by the SecB chaperone, whereupon they
are translocated across the IM through SecYEG in an unfolded state
[71,72]. The unfolded OMPs must be protected from aggregation
and must be able to traverse the periplasm, including the peptido-
glycan layer, and then correctly fold and insert into the OM [73].
These requirements suggest that transport across the periplasm
and membrane insertion may be facilitated processes and, indeed,
a number of periplasmic and OM-associated proteins have been
implicated in the OMP assembly pathway [73]. These proteins
can be roughly grouped into three categories: proteases; chaper-
ones which stabilise unfolded and non-native conformations of
their client proteins; and folding catalysts, which catalyse rate-lim-
iting steps in folding (Fig. 4a and b) [73].
Fig. 3. The cell envelope of Gram-negative bacteria. (a) The cytoplasm of E. coli is surrounded by the inner membrane (IM), the periplasm and the outer membrane (OM). The
IM is a symmetric phospholipid (shown in orange) bilayer containing integral a-helical membrane proteins. The OM is an asymmetric bilayer of phospholipid and
lipopolysaccharide (LPS, shown in purple) and contains b-barrel integral membrane proteins. The periplasm is the aqueous compartment between the two membranes in
which the peptidoglycan cell wall is found. Both membranes have associated lipoproteins on their periplasmic faces. (b) The lipid composition of the IM (light blue), inner
leaﬂet of the OM (dark blue) and outer leaﬂet of the OM (white) in E. coli (percentages based on those reported in [64–66]). Structures of (c) LPS, (d)
phosphatidylethanolamine, (e) phosphatidylglycerol and (f) cardiolipin are shown.
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it is unsurprising that the presence of unfolded OMPs in the peri-
plasm is a strong inducer of the envelope stress response [73]. Ex-
posed C-terminal residues of misfolded OMPs are recognised by
the PDZ domain of the inner membrane-associated protease, DegS
(Fig. 4a), activating the protease domain [74]. Activated DegS trig-
gers a proteolytic cascade which leads to induction of the rE heat-
shock response [73,74]. Using the assumption that depletion of
periplasmic chaperones will cause an increase in misfolded OMPs,
identiﬁcation of many of the known periplasmic folding factors ar-
ose by genetic studies of bacterial strains showing high rE activity
[67]. Some of the key periplasmic assistants of OMP folding, includ-
ing SurA, Skp, DegP and FkpA (Fig. 4), are described in the following
sections.
SurA
SurA was ﬁrst identiﬁed in 1990 when it was shown to be
required for the survival of E. coli in the stationary phase [75].
Initial characterisation described SurA as a parvulin-like pepti-
dyl-prolyl isomerase (PPIase) involved in the proper assembly
of major OMPs [67,76,77]. Trypsin digestion of OMPs in surA
deletion mutants showed that not all OMPs have increased rates
of proteolysis, leading to the conclusion that SurA is not an
essential folding factor [76]. The amounts of FadL, LamB, OmpA,
OmpC, OmpF, OmpX and LptD, however, were all found to be re-
duced in surA deletion strains [78]. Similar results were obtained
using a proteomic analysis, which also revealed an upregulation
of proteins under the control of the rE regulon in surA deletion
strains [79].
Crystallisation of SurA revealed a four-domain protein with two
PPIase domains (P1 and P2) sandwiched between the N- and C-ter-
minal domains (Fig. 5a) [80]. PPIase domain P1 is packed againstthe core structure of the N- and C-terminal domains and does
not show signiﬁcant activity, while the more active P2 domain ex-
tends away from the core structure [77,80,81]. The PPIase activity
of P2 has been shown to be increased in the presence of the adja-
cent chaperone domain, presumably as this domain facilitates sub-
strate binding close to the active site of P2 [82]. Deletion of both
PPIase domains, however, did not cause a signiﬁcant loss of SurA
function in vivo and the isolated PPIase domains failed to comple-
ment activity in surA deletion mutants [81]. This led to the conclu-
sion that SurA functions mainly as a chaperone [81]. Interestingly,
mutations which would be expected to cause a loss of PPIase func-
tion in the P1 domain, if this domain were active, destabilised SurA
in vitro but increased chaperone activity in vivo [83]. This result
suggests a regulatory function of the P1 domain, explaining its lack
of signiﬁcant PPIase activity [83].
Binding studies using peptide sequences have been carried out
on SurA in vitro, revealing a preference for aromatic-rich se-
quences with an Ar-X-Ar motif [84,85]. Peptide sequences con-
taining this motif bind to SurA with dissociation constants in
the micromolar range [84], suggesting that SurA binds to OMPs
by recognition of this motif, which is frequently found in OMP
C-terminal regions [78,86]. The C-terminal Y-X-F motif is respon-
sible for activating DegS and triggering the rE stress response
[73,78] and, interestingly, it has been reported that SurA does
not show signiﬁcant binding afﬁnity to this motif [87]. In contrast
with the peptide binding data, only a few studies have reported
the binding of full length OMPs to SurA [88–91] and one study
failed to detect stable SurA:OMP complexes [92]. The available
data, however, suggest that unfolded OMPs are bound by SurA
in preference to unfolded soluble proteins, while folded proteins
do not bind [89]. While the polypeptide binding site of SurA has
not been identiﬁed conclusively, an extended crevice, located in
Fig. 4. Schematic of the current model of biogenesis and chaperoning of OMPs in
E. coli. (a) OMPs are synthesised on the ribosome before post-translational
translocation across the inner membrane by the SecYEG translocon. Unfolded
OMPs are then chaperoned across the periplasm to the b-barrel assembly
machinery (BAM) complex, which aids folding and insertion into the OM. BAM
complex proteins are labelled A–E, and the periplasmic polypeptide transport-
associated (POTRA) domains of BamA are labelled P1-5. Horizontal black lines
indicate the approximate position of the inner and outer membranes. (b) Flow
diagram of the periplasmic and outer membrane-anchored proteins which may be
implicated in OMP biogenesis. (a) was adapted from [92] with permission from
Elsevier,  2013, while (b) was reproduced from [73] with permission from John
Wiley and Sons,  2005.
Fig. 5. Crystallographic structures of selected periplasmic chaperones. (a) Ribbon
diagram of SurA coloured as follows N-terminal domain (blue), PPIase domain P1
(green), PPIase domain P2 (orange) and C-terminal domain (red) (1M5Y [80]). (b)
Ribbon diagram of Skp trimer with the subunits A, B and C coloured in green,
magenta and blue, respectively, (1U2M [104]). The tips of the a-helices in subunits
A and B have been modelled. (c) Ribbon diagram of the FkpA dimer showing the N-
terminal chaperone domains (red and orange) through which dimerisation occurs
and the C-terminal PPIase domains (blue) (1Q6H [109]). (d) Ribbon diagram of the
Spy dimer with the monomers coloured individually in red and blue (3O39 [114]).
(a), (c) and (d) were generated from PDB ﬁles using the accession numbers given in
brackets using UCSF Chimera molecular visualisation application [236]. (b) was
reproduced from [104] with permission from Elsevier,  2004.
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is thought to be the site through which SurA:client interaction oc-
curs [80].
Sklar and co-workers demonstrated that depletion of SurA
causes a loss of OM density, suggestive of OMP assembly defects,
that was not observed when the other periplasmic folding factors,
Skp and DegP, were depleted [93]. Additionally, SurA has been
shown to be localised at the OM [84] and is the only periplasmic
folding factor to have been successfully cross-linked to BamA of
the b-barrel assembly machinery (BAM) complex in vivo [93]. It
is not yet known, however, if SurA binds directly to BamA, or if this
interaction is mediated through SurA-bound substrates [86].
Together, these observations have led to the hypothesis that SurA
is the main chaperone for OMP transport in vivo [93,94], althoughthere is clearly much to learn about the function of this protein at
both cellular and molecular levels.
Skp
Although Skp had previously been suggested to be a DNA-bind-
ing protein, an OMP and an LPS binding protein, it is now known
that Skp is a periplasmic protein, as evidenced by the N-terminal
signal sequence which targets Skp for translocation across the in-
ner membrane [73]. Depletion of Skp in vivo led to a moderate
reduction of OmpC, OmpF, OmpA and LamB in the OM fraction
[95]. These cells, however, were still viable demonstrating that
Skp is not essential. Further genetic studies revealed that both
the skp surA deletion mutant and the degP surA deletion mutant re-
sult in a synthetic lethal phenotype, leading to the prevailing
hypothesis that the periplasmic chaperones Skp and DegP act on
redundant pathways seperate to SurA (Fig. 4a) [94]. Proteomic
analysis of a skp deletion mutant suggested that none of the OMPs
identiﬁed were affected signiﬁcantly; however, depletion of SurA
in the skp null strain reduced the levels of almost all OMPs, consis-
tent with the hypothesis of parallel chaperone pathways [96].
While this hypothesis explains many of the observations above,
the accumulation of protein aggregates in the periplasm of skp degP
deletion mutants suggests that Skp may have a role in maintaining
the solubility of at least some OMPs prior to folding [97]. Addition-
ally, skp fkpA deletion mutants showed defects in the folding of
LptD, an essential OMP involved in LPS synthesis [98]. Over-
expression of SurA could not ameliorate these effects [98]. To-
gether, these results suggest that the chaperone pathways in the
periplasm may be inter-dependent.
The chaperone activity of Skp in OMP folding was conﬁrmed re-
cently by the ﬁnding that Skp binds with high afﬁnity (Kd nM) to
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was shown to occur via the transmembrane domain of OmpA
[95]. NMR spectroscopy conﬁrmed that the transmembrane
domain of OmpA is Skp bound, while the periplasmic domain is
free to fold independently in solution [100]. Interaction of unfolded
OMPs with Skp is thought to occur early after translocation across
the IM, as evidenced by the ability to cross-link Skp to the OMP
PhoE at the periplasmic side of the IM in spheroplasts [101]. Skp
has also been shown to be required for the release of newly-trans-
located OmpA from the periplasmic side of the IM in spheroplasts
[97], suggesting that the N-terminal residues of the client protein
may interact with Skp as they emerge from the translocon. This
hypothesis was supported by Förster resonance energy transfer
(FRET) experiments which showed that the N-terminal residues
of OmpC enter the Skp cavity ﬁrst [102]. Molecular dynamics
(MD) simulations yielded similar results [102].
Skp is a trimeric protein in solution with a structure that has
been described as ‘‘jellyﬁsh-like’’ (Fig. 5b) [103,104]. A b-barrel do-
main forms the body of the jellyﬁsh, with long a-helical ‘‘tentacles’’
protruding from the b-barrel [103,104]. Skp is a basic protein, with
a theoretical isoelectric point (pI) around 9.5 [73]. The charge dis-
tribution of Skp is notable, with many basic residues clustered
around the tips of the a-helical tentacles resulting in a large mac-
rodipole moment [103,104]. This unusual distribution of charges
suggests a role of Skp in substrate delivery to negatively charged
membranes. Additionally, a putative LPS-binding site was identi-
ﬁed on the outer edge of the Skp a-helices, similar to an LPS-bind-
ing motif found on the OMP FhuA [104]. This ﬁnding led to the
suggestion that Skp may act as a stress chaperone, acting to rescue
OMPs which veer off the SurA chaperone pathway [105].
The a-helical domains of Skp deﬁne a central cavity enriched
with hydrophobic residues, which has been shown to be involved
in sequestering unfolded substrates to prevent their misfolding
and aggregation [88,90,100,102–104]. In contrast with SurA, no
common binding motif has been identiﬁed for the interaction of
Skp with its substrates [73,90] and both electrostatic and hydro-
phobic interactions have been implicated as being important for
binding [99,102,106]. In the absence of a speciﬁc binding motif,
the high afﬁnity interaction between Skp and its substrates has
been shown to arise from the formation of a large number of simul-
taneous weak interactions that exist between the chaperone and its
substrate [90]. Despite a low sequence identity, Skp shares a strik-
ing structural resemblance to prefoldin [104], an ATP-independent,
cytosolic chaperone in eukaryotes and archaea, which protects par-
tially folded proteins from aggregation and passes clients to other
chaperones to promote folding [103,104]. The transient nature of
the multitude of weak, local interactions between Skp and its sub-
strates has also been hypothesised to facilitate handover of sub-
strates to other chaperones [90], which could point to functional,
as well as structural similarities, between these ATP-independent
chaperones. Conformational analysis of Skp-bound OmpX revealed
a highly ﬂexible, but compact, ensemble which lacks secondary
structure [90], in contrast with the molten globule-like conforma-
tions of substrates bound by ATP-dependent chaperones such as
GroEL [107]. This difference in substrate binding provides further
evidence that ATP-independent chaperones, such as Skp, rely on a
thermodynamic gradient for substrate release and subsequent fold-
ing [90,108]. In this model, the large free energy of folding of OMPs
provides a ‘‘thermodynamic sink’’ that drives the release of these
client proteins from Skp and enables their subsequent folding in
the OM [108]. The ability of Skp to prevent aggregation of water-
soluble proteins has also been shown using clients including lyso-
zyme [104] and single chain antibodies [106], revealing that Skp
is able to chaperone soluble proteins as well as OMPs. Skp may,
therefore, act as a universal chaperone assisting the folding of both
soluble proteins and OMPs in the periplasm.Other periplasmic folding factors
While SurA and Skp are currently the most studied of the
periplasmic folding factors, other proteins have been shown to par-
ticipate in OMP biogenesis. Three other periplasmic PPIase en-
zymes are currently known: PpiA, PpiD and FkpA [64]. While
PpiA has been shown to have the highest activity of these proteins
in vitro, its deletion had no detectable effect on the assembly of
OMPs in vivo and, as yet, no evidence has directly linked PpiA to
OMP biogenesis [64,73]. In contrast, deletion of the inner mem-
brane-anchored PpiD (Fig. 5a) was reported to cause a reduction
in the levels of OmpC, OmpF, OmpA and LamB in the OM of the
mutant cells and a ppiD surA deletion mutant was reported to be
lethal, implicating PpiD in OMP folding [64,73]. Later studies did
not replicate these ﬁndings, however, and the role of PpiD in
OMP assembly remains an open question [64].
FkpA, like SurA, is an example of a dual PPIase-chaperone fold-
ing factor and fkpA null mutants have been shown to be viable, but
to display increased OM permeability and an up-regulation of peri-
plasmic proteases [67]. Structural studies revealed that FkpA has a
C-terminal PPIase domain, appended to an N-terminal chaperone
domain that mediates dimerisation to form a v-shaped cleft
(Fig. 5c) [109]. It has been hypothesised that substrate binding oc-
curs in this cleft [109], but no data are currently available to sup-
port this. Until recently, chaperone activity of FkpA had been
reported only for soluble protein substrates and the involvement
of FkpA in OMP biogenesis was not well supported [64,109]. Crea-
tion of a skp fkpA deletion mutant by Schwalm and co-workers,
however, showed that folding of LptD is compromised in this
strain, providing the ﬁrst evidence that FkpA may indeed chaper-
one OMPs in the periplasm [98].
Another example of a dual-function chaperone in the periplasm
is the protease-chaperone DegP which, alongside DegS, belongs to
the HtrA family of proteases [73]. Temperature changes were ini-
tially thought to cause the switch between the two activities of
DegP, with the chaperone activity dominating at 28 C and the pro-
tease activity becoming dominant at 42 C [73]. Structure–function
analysis of DegP concluded that the resting state of this protein is a
hexamer, in which the interactions between subunits block the
protease sites and the central cavity is large enough to accommo-
date unfolded substrates [110]. Similarly to DegS, DegP recognises
the C-terminal residues of misfolded OMPs via its PDZ domains and
this was thought to cause structural reorganisation to larger
proteolytically-active oligomers comprised of 12 or 24 DegP
monomers [78,111,112]. Cyro-electron microscopy of DegP in the
presence of OmpC revealed a tetrahedral arrangement of DegP tri-
mers with the inner cavity ﬁlled by a cylindrical area of electron
density into which the structure of folded OmpC could be modelled
[111]. This led to the conclusion that the fate of DegP-bound sub-
strates lies in their ability to adopt their native structure within the
cavity, as only unfolded substrates can be degraded [111]. Recent
data using cage-deﬁcient mutants of DegP, which can only associ-
ate into trimers, revealed that these variants are able to bind and
degrade substrates without the need to form higher order oligo-
mers, suggesting that cage formation in response to substrate
binding may be linked solely to the chaperone function of this pro-
tein [113].
The most recently discovered periplasmic chaperone, Spy, was
identiﬁed by its over-expression in bacterial strains expressing
unstable periplasmic proteins [114]. In vitro characterisation of
Spy revealed it to be an effective chaperone, suppressing aggrega-
tion and protecting substrates from inactivation by tannins [114].
Spy has a novel a-helical cradle structure, which is unlike that of
any known chaperone (Fig. 5d) [114]. It is not known, currently,
whether Spy is involved in OMP biogenesis, but the discovery of
a previously unknown chaperone only two years ago highlights
that there is much still to be learned about the chaperone network
Fig. 6. Structure of the BAM complex. (a) Schematic of the E. coli BAM complex with
BAM proteins labelled A–E and POTRA domains labelled P1–5 (reproduced from
[92] with permission from Elsevier,  2013). (b) Crystal structure of N. gonorrhoeae
BamA (4K3B [120]). The b-barrel domain is shown in orange. POTRA domains are
labelled as in (a) and are shown in pink, blue, green, purple and yellow. (c) Crystal
structure of E. coli BamB (3P1L [130]). The blades of the b-propeller structure are
coloured individually and labelled 1–8. (d) Crystal structure of the N-terminal
domain of E. coli BamC (dark blue) bound to BamD (2YHC [125]). The ﬁve TPR motifs
of BamD coloured in light blue, yellow, green, pink and orange. (e) Lowest energy
structure of E. coli BamE solved by NMR spectroscopy (2KXX [237]). All images were
generated from the PDB ﬁles using the accession numbers given in brackets using
UCSF Chimera molecular visualisation application [236].
272 L.M. McMorran et al. / Archives of Biochemistry and Biophysics 564 (2014) 265–280in the E. coli periplasm. In addition to the complexity evident in a
single species, studies on the periplasmic chaperones of Neisseria
meningitides show that SurA deletion causes no detectable defects
in OMP assembly, while deletion of Skp caused lower levels of
some porins, but not all OMPs [115]. Complementation of the skp
null mutant was not possible using E. coli Skp, suggesting that peri-
plasmic chaperones may act in a species-speciﬁc manner, making
the derivation of generic principles of periplasmic chaperoning dif-
ﬁcult to achieve [115].Insertion into the outer membrane
Following chaperone-assisted transport across the periplasm,
unfolded OMPs must insert and fold into the OM, a process which
is assisted by the BAM complex [116]. The BAM complex in E. coli
(Fig. 6a) is comprised of the outer membrane protein BamA
(previously YaeT, Fig. 6b) and four accessory lipoproteins, BamB
(YfgL, Fig. 6c), BamC (NlpB, Fig. 6d), BamD (YﬁO, Fig. 6d) and BamE
(SmpA, Fig. 6e) [105,116]. BamA is an essential protein, the deple-
tion of which causes an accumulation of aggregated OMPs in the
periplasm, leading to cell death [117]. BamA belongs to the con-
served Omp85 super-family ﬁrst identiﬁed in N. meningitides
[118]. Homologues are also found in mitochondria (Sam50) and
chloroplasts (Toc75) [119]. All of the BamA homologues identiﬁed
thus far have a C-terminal transmembrane b-barrel domain and a
water-soluble N-terminal region [116]. The structure of the BamA
b-barrel in two different organisms has been elucidated recently,revealing it to be 16-stranded with a conserved VRGY motif in loop
L6 which is thought to be functionally important (Fig. 6b) [120].
The N-terminal soluble region of BamA comprises different
numbers of polypeptide transport-associated (POTRA) domains,
dependent on the identity of the organism. Bacterial BamA homo-
logues tend to have ﬁve POTRA domains. Toc75 in chloroplasts,
however, has three POTRA domains and Sam50 in mitochondria
has only one POTRA domain [116]. Crystallisation of the four N-ter-
minal POTRA domains (POTRAs 1–4) of E. coli revealed that despite
their low sequence identity, the overall fold (a 3-stranded b-sheet
with 2 a-helices) is conserved (Fig. 6b) [119]. Previous studies of
the binding of OMPs revealed a direct interaction of BamA with un-
folded OMPs and peptides mimicking the conserved aromatic-rich
C-terminal sequence of OMPs [121]. Evidence of b-augmentation
between POTRA domains of neighbouring proteins in the crystal
structure of E. coli POTRA domains 1–4 suggests a possible mecha-
nism for substrate binding [119]. Deletion of individual POTRA do-
mains from BamA demonstrated that one of the functions of these
soluble domains is to provide a scaffold for the association of the
lipoproteins which make up the BAM complex with BamA [119].
Interestingly, while POTRAs 3–5 are essential for cell viability in
E. coli, only POTRA 5 is essential in N. meningitides [116], suggesting
differences in the roles of these conserved domains between bacte-
rial species.
Of the four accessory lipoproteins in the BAM complex, only
BamD has been shown to be essential for cell viability in E. coli,
implying an important role for this lipoprotein in OMP biogenesis
[116]. BamD is a predominantly a-helical protein with 5 tetratric-
opeptide repeat motifs (Fig. 6d), sharing structural similarity with
other proteins which recognise C-terminal targeting sequences
[122]. BamD interacts with BamA via POTRA domain 5 [116] and,
accordingly, a mutation in POTRA 5 of BamA that is lethal at
37 C causes dissociation of BamA from the BamCDE subcomplex
[123]. Recent experiments in vivo using point mutations in BamD
and BamA have suggested that BamD regulates the activity of
BamA [123,124]. Co-crystallisation of BamD with the non-essential
lipoprotein BamC (Fig. 6d) revealed that a binding pocket in the
N-terminal region of BamD is the site of interaction of these two
lipoproteins [125]. A truncated variant of BamD was used to dem-
onstrate binding of this lipoprotein to synthetic peptides based on
the OMP C-terminal targeting sequence, and this interaction oc-
curred at the same binding pocket as the interaction with BamC
[116,125]. Together, these data have led to the hypothesis that
BamC may act as a regulator of BamD substrate binding [116],
although the precise role of BamC (which has been shown to span
the OM with parts of its sequence exposed to the extracellular
environment (Fig. 6a) in OMP assembly remains unclear [126].
BamE (Fig. 6e) is the most recently discovered accessory lipo-
protein of the BAM complex. This lipoprotein associates with the
BAM complex via interaction with BamD and has been shown to
cause only minor defects in OMP assembly when depleted
[116,127]. NMR spectroscopy revealed that BamE binds preferen-
tially to PG lipids [127]. These lipids have been shown to enhance
the insertion of OMPs into liposomes in vitro [116], suggesting that
a role of BamE may be to promote OMP insertion into the OM.
Interestingly, in DbamE and BamD R197L expressing strains of
E. coli, BamA becomes more susceptible to degradation by protein-
ase K, suggesting that BamE might also be involved in conforma-
tional modulation of BamA [124,128]. While BamC and BamE are
associated with BamA via interaction of BamD with the soluble PO-
TRA domains, BamB (Fig. 6c) [129–132] is associated directly with
BamA via POTRAs 2–5 (Fig. 6a) [116,119]. Although not essential
for cell viability, deletion of BamB results in reduced OMP assem-
bly and a phenotype similar to SurA depletion mutants [133].
The OMPs most affected by deletion of BamB are those with larger
b-barrels and, thus, it has been suggested that BamB has a role in
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binding capacity of the BAM complex [116]. Indeed, BamB and
BamD have been shown recently to bind to unfolded OmpA and
unfolded BamA in the absence of the other BAM components
[134]. Interestingly, both BamB and BamD accelerate BamA assem-
bly into liposomes, however, OmpA folding was not similarly as-
sisted by either lipoprotein, suggesting that one role of the BAM
lipoproteins is to facilitate assembly of BamA [134].
Exciting recent work by Kahne and colleagues has demon-
strated that the BAM complex can be reconstituted in a functional
form in vitro [135]. The complex was found to have a 1:1:1:1 ratio
of BamA:B:C:D, but the stoichiometry of BamE could not be deter-
mined due to its small size [135]. The activity of the BAM complex
was monitored using the folding of the OM b-barrel peptidase en-
zyme, OmpT, which can be measured directly by cold SDS–PAGE or
indirectly by following OmpT enzymatic activity [135,136]. Com-
pared with experiments in which the intact BAM complex was
present, OmpT folding efﬁciency was reduced by approximately
6-fold in the absence of BamB [135,136]. Reduced OmpT folding
efﬁciency was also observed in the absence of SurA, even when
the intact BAM complex was present [135], supporting the previ-
ous suggestion that BamB and SurA have similar, but not redun-
dant, roles in vivo [116,135]. These results also demonstrate that
the BAM complex is able to complete the OMP assembly cycle
without the aid of additional cellular components [136].
The mechanism of action of the BAM complex during OMP fold-
ing and membrane insertion is still under debate and several mod-
els have been proposed [116]. These include substrate translocation
across the OM through BamA, followed by folding into the OM from
outside the cell. Alternatively, the BamA b-barrel may act as a scaf-
fold for b-sheet formation for the folding OMP or formation of BamA
multimers may create a pore in the OM through which the sub-
strate can insert [116]. Recent elucidation of the crystal structure
of BamA from two different organisms, however, shows a large cav-
ity in the BamA b-barrel within which a substrate could be accom-
modated [120]. Additionally, MD simulations point to the existence
of a lateral gate in the BamA b-barrel, potentially allowing sub-
strates to move from the barrel interior into the membrane [120].
The observation of two conformations of BamAwith different resis-
tance to proteinase K has been observed previously [124,128].
These data and the observation that the conserved L6 loop is only
accessible for labelling in one conformation [124], suggest that
opening of the lateral gate may be modulated by movements of
the L6 loop. Indeed, structural studies of BamA [120] and two
homologues, FhaC [137] and TamA [138], revealed that the L6 loop
adopts a different conformation in the FhaC crystal structure to that
observed in the TamA and BamA crystal structures. This may sug-
gest that L6 loop movements are a conserved functional feature
across the Omp85 super-family. Lateral opening in TamA [138]
has also been suggested MD simulations suggest, however, that
FhaC does not share this functional feature [120]. These differences
may be reﬂective of differences in substrate handling by these
OMPs, with FhaC exporting substrates across the OM, while TamA
and BamAmost likely insert substrates directly into the OM. In con-
trast with the wealth of information about themechanism of action
of many cytosolic chaperones and chaperonins [41,139,140], there
is clearly much to learn about the mechanism of action of the
BAM complex and its associated periplasmic chaperones in facili-
tating the folding and membrane insertion of OMPs.Application of different biophysical methods to the study of
OMP folding into lipid bilayers
In recent years, many techniques have been developed to study
the folding of water-soluble proteins and together these haveyielded a near-atomistic view of the folding landscapes of many
such proteins [31]. By contrast, the experimental toolbox for the
study of membrane protein folding is more limited [141]. Much
of the information available about OMP folding into lipid bilayers
has resulted from the use of techniques such as cold SDS–PAGE
(where samples are not boiled prior to loading, resulting in the dif-
ferential migration of the folded and unfolded conformations of the
OMP [142]) and tryptophan ﬂuorescence emission and far-UV cir-
cular dichroism (CD) spectroscopies on a limited subset of proteins,
as summarised below and in Table 1. In spite of the challenges
faced, the development of new methodologies and the application
of existing methods to study OMP folding are now beginning to
yield knowledge of OMP folding mechanisms both in the presence
and absence of chaperones.
As well as the methods mentioned above, the quenching of
tryptophan ﬂuorescence has been utilised successfully to follow
the folding and membrane insertion of OmpA [143,144]. In this
technique, lipids which are brominated at different positions in
the acyl chain are introduced into liposomes. The depth of mem-
brane insertion of an OMP during a folding reaction is measured
by following the kinetics of tryptophan ﬂuorescence quenching
by the bromine atoms within the bilayer [144]. Additionally, the
use of mutagenesis to create OmpA variants with only a single
tryptophan residue allowed the insertion of different regions of
the OmpA b-barrel into the bilayer to be monitored. For example,
varying the location of a single tryptophan residue can yield infor-
mation on whether individual secondary structural elements are
inserted sequentially or simultaneously [143]. Alongside other
spectroscopic techniques, these experiments provided the ﬁrst evi-
dence of how an OMP folds, revealing that the folding and mem-
brane insertion of OmpA is a concerted process [143,144].
NMR studies on unfolded water-soluble proteins has provided
evidence that the starting point of folding is not a random coil
structure [22,23,28,145,146]. Indeed, residual structure in the un-
folded state has been suggested to be important in initiating fold-
ing by facilitating the collapse of the polypeptide chain into
conformations able to fold efﬁciently to the native state [22]. In
contrast with helical IM proteins, OMPs can be denatured in urea
or guanidine hydrochloride (GuHCl), enabling studies of their fold-
ing using classic Anﬁnsen-style experiments [43]. Analysis of the
urea denatured state of OmpX has shown that the protein is glob-
ally unfolded, but has two regions of non-random structure: one a
hydrophobic cluster and the other a helical region [147]. Analysis
of peptides corresponding to these regions showed independent
binding of the clusters to detergent micelles, suggesting a role of
residual structure in the unfolded state in the initiation of OMP
folding and membrane insertion [148]. The application of NMR
spectroscopy to folded membrane proteins is complicated by the
need to ﬁnd a suitable mimic of the membrane environment.
Detergent micelles are widely used, but problems with long term
stability and the maintenance of proteins in a functional state are
commonly encountered [149]. As a result, development of alterna-
tive non-micellar systems such as bicelles, nanodiscs and amphip-
ols, to stabilise the folded state of membrane proteins has become
an active research area [149–151] and is reviewed elsewhere in
this issue.
Detailed information about the folding mechanisms of water-
soluble proteins has been obtained by measuring the folding and
unfolding kinetics of the protein of interest, using a spectroscopic
probe to monitor the reaction time-course in the presence of vary-
ing concentrations of denaturant. The logarithm of the kinetic rate
constants acquired from these data can be plotted against the
denaturant concentration, giving a characteristic v-shaped chevron
plot [152]. If the limbs of the chevron remain linear over denatur-
ant concentrations from 0 M to the highest concentration used
(highly denaturing) and the free energies associated with the
Table 1
Summary of selected in vitro folding studies of outer membrane proteins (OMPs) into lipid bilayers.
Protein Notes Techniques used Selected References
OmpA Folding studies of OmpA are described in this review and elsewhere. Cold SDS–PAGE, far-UV CD, Trp
ﬂuorescence
Kleinschmidt (2006) [171]; Otzen (2013)
[58]
PagP Folding studies of a C-terminally his-tagged construct of PagP (HT
PagP) and untagged construct (PagP) are described in detail in this
review.
Cold SDS–PAGE, far-UV CD, Trp
ﬂuorescence, U-value analysis
Bishop et al. (2000) [239]; Ahn et al. (2004)
[206]; Huysmans et al. (2010) [157]
hVDAC Human voltage-dependent anion-selective channel (hVDAC) can be
folded to the native state in LUVs composed of lipids of varying acyl
chain length (diC10:0PC to diC18:1PC). Folding yield was estimated to
be 94% in diC12:0PC LUVs. Secondary structure content of hVDAC in
diC12:0PC LUVs was not affected by changing pH from 7.0 to 3.0.
Cold SDS–PAGE, far-UV CD, Trp
ﬂuorescence, sucrose density gradient
centrifugation and proteolysis
Shanmugavadivu et al. (2007) [225]
FomA FomA can be folded to the native state in both diC10:0PC and
diC18:1PC (LUVs and SUVs). Kinetic analysis of folding into diC10:0PC
and diC18:1PC SUVs suggested that FomA folds via parallel pathways
into both lipids. The folding halftime is dependent on acyl chain
length and reaction temperature.
Cold SDS–PAGE, Trp ﬂuorescence, far-
UV CD
Pocanschi et al. (2006) [202]
OmpG The porin OmpG reconstituted in native E. coli lipids is gated by
conformational changes in extracellular loops in a pH-dependent
manner (closed at pH 5.0). Unfolding under force reveals each b-
hairpin unfolds individually. Refolding from this mechanically
unfolded state also proceeds by sequential folding of individual b-
hairpins.
Atomic force microscopy (AFM) Sapra et al. (2009) [240]; Damaghi et al.
(2010) [241]; Mari et al. (2010) [242];
Damaghi et al. (2011) [243]
OmpF Refolding of urea-solubilised OmpF into diC14:0PC SUVs occurred at
only 15% yield. Refolding kinetics were biphasic but much slower
than OmpA.
Cold SDS–PAGE, Trp ﬂuorescence, far-
UV CD
Surrey et al. (1996) [244]
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free energy, the data suggest that the protein under study probably
folds via a two-state mechanism [13,14]. Deviations from linearity,
termed rollover, in either limb can occur and have been interpreted
to indicate the presence of a folding intermediate [152,153], move-
ment of the transition state [154] or aggregation [155]. As well as
being an indicator of folding mechanism (alongside equilibrium
folding analysis), chevron plot analysis also yields information
about the compactness of the transition state (or any populated
intermediates) and their position on the folding reaction coordi-
nate [152]. This detailed kinetic analysis is routine in the study
of water-soluble protein folding and its recent application to study
the folding of OmpA [156] and PagP [157] will be discussed later in
this review.
Protein engineering methods coupled to kinetic analysis have
been the most successful tool to probe the folding mechanisms
of membrane proteins and have been applied to the IM proteins
bR [44,158,159] (Fig. 2b), DsbB [160] and the OMP, PagP (Fig. 2d)
[157]. U-Value analysis is a powerful protein engineering ap-
proach, which can be used to map the formation of contacts in
the transition states and populated intermediates formed during
protein folding (Fig. 7) [161–163]. In this approach, speciﬁc side-
chain interactions are deleted by mutation, and the effect on the ki-
netic and thermodynamic parameters of the variant protein is
measured and compared with wild-type [163]. The amino acid
substitution may cause a change in the free energy of activation
(kinetic), the equilibrium (thermodynamic) free energy of the fold-
ing reaction, or both. The ratio of these changes is the U-value,
which is usually between 0 and 1, and gives a measure of the
change of stability of the transition state (or intermediate), com-
pared with the change in stability of the native state [163]. Both
stabilities are measured relative to the denatured state, whose free
energy is assumed to be unaffected by the mutation [163].
U-Values close to zero indicate that the transition state (or
intermediate) is unstructured in the region of the amino acid
substitution, while higher U-values indicate that the region is
structured in the transition state (or intermediate) [161,162]. Par-
tial U-values are also observed and can be interpreted in several
ways. For example, partial U-values may result if native contacts
are partially formed in the transition state (or folding intermedi-
ate) or if multiple folding routes exist [163]. U-Values haveprovided a wealth of information on the structure of partially
folded intermediates and transition states of water soluble pro-
teins, revealing detailed information about their folding mecha-
nisms [163]. Furthermore, the use of experimental U-values as
constraints in MD simulations allows atomistic models of these
ensembles to be created [164]. The main stumbling block for the
application of U-value analysis to OMPs is the need to ﬁnd exper-
imental conditions that enable reversible folding for the protein of
interest, which has proved difﬁcult for many OMPs [58,156,165].Folding studies of OMPs in vitro
OmpA
The study of OMP folding in vitro has been pioneered by work
on the monomeric, 8-stranded ion channel OmpA (Fig. 2e) from
E. coli. Initial experiments using a combination of cold SDS–PAGE
and protease digestion were conducted by Schweizer et al. as early
as 1978 [166], which demonstrated that OmpA can fold in the
presence of LPS and Triton X-100 detergent. It was not until over
a decade later that Surrey and Jähnig reported the folding of OmpA
into lipid bilayers [167], opening the door to studies of membrane
protein folding in a more native-like environment. OmpA, solubi-
lised in 8 M urea, was shown by these authors to insert spontane-
ously into small unilamellar vesicles (SUVs) of diC14:0PC upon rapid
dilution from urea [167]. Detailed kinetic studies were carried out
by these, and other, authors on the refolding of urea-unfolded
OmpA into liposomes using cold SDS–PAGE, far-UV CD and trypto-
phan ﬂuorescence emission [143,168,169]. Kinetic measurements
of the formation of secondary structure by far-UV CD and tertiary
structure by tryptophan ﬂuorescence emission revealed that these
structural elements form concomitantly [170]. Additionally, the
rate of quenching of single tryptophan mutants of OmpA by bromi-
nated lipids suggested that the 8 b-strands penetrate the mem-
brane simultaneously [144]. Based on these data a scheme for
the refolding pathway of OmpA was proposed, beginning with col-
lapse of the protein in aqueous solution, followed by adsorption to
the membrane surface and folding to the native state by progres-
sive penetration deeper into the membrane as the b-barrel forms
(Fig. 8) [143,144,168,169]. These experiments provided the ﬁrst
Fig. 7. Schematic of the principles of U-value analysis. (a) A mutation (shown as a red dot) is made in a region of the protein which is native-like in the transition state ()
leading to equal destabilisation of  and the native state (N) resulting in a U-value of 1 or (b) a mutation is made in a region of the protein which is unfolded in  but
structured in the native state, leading to destabilisation of N only and aU-value of 0. It is assumed that the mutation does not affect the free energy of the unfolded ensemble
(U). Abbreviations: DDGU–N refers to the difference in the free energy of folding upon mutation and DDGU– refers to the difference in the free energy between U and  upon
mutation. This image was adapted with permission from G.H.M. Huysmans.
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insertion [143,144,168,169,171].
More recently, measurement of the stability of OmpA has
been achieved in several membrane mimetic environments
[156,172,173]. Finding experimental conditions under which
membrane protein folding is fully reversible and reaches equilib-
rium on experimentally tractable timescales in vitro is challenging
and continues to impede studies of membrane protein folding and
stability [174]. Folding of OmpA into SUVs composed of 92.5%
C16:0C18:1PC and 7.5% C16:0C18:1PG was reported to be reversible
[172]. Good agreement of the rate of folding when measured by
tryptophan ﬂuorescence emission and cold SDS–PAGE implied a
two-state folding mechanism [172]. Introduction of guest lipids
into this reversible system allowed the effects of bilayer thickness
and the extent of lipid acyl chain saturation on OmpA stability to
be measured, revealing that forces within the bilayer, such as cur-
vature stress, affect thermodynamic stability [172]. Kinetic analy-
sis of OmpA refolding into large unilamellar vesicles (LUVs) of
varying diameter conﬁrmed the role of curvature elastic stress in
modulating the folding rate, suggesting that the irreversibility of
folding observed for OmpA into LUVs may be a kinetic trapping ef-
fect [175].
Establishing conditions under which OmpA folds reversibly
allowed double mutant cycle analyses of the role of side-
chain-side-chain interactions in the protein folding mechanism
[176,177]. After investigating residues involved in OmpA function
[176], this method was used to probe how the interactionsFig. 8. Proposed mechanism of folding and insertion of the OmpA b-barrel domain
into lipid bilayers in vitro. (a) Depicts an unfolded, membrane-bound state, (b)
depicts a partially folded and inserted state, and (c) depicts the native state.
Coloured circles indicate the location of tryptophan residues in the OmpA structure.
Reproduced from [238] with permission from Elsevier,  2011.between aromatic residues in the intrafacial region of the b-barrel
contribute to stability [177]. In both a-helical and b-sheet mem-
brane proteins, aromatic residues are enriched in the intrafacial
region forming ‘‘aromatic girdles’’ [178]. This common feature of
OMPs has been hypothesised to stabilise the b-barrel and to ﬁx
the location of proteins in the lipid bilayer, based on the partition-
ing energies of small model peptides into a model bilayer from
aqueous solution [179]. Indeed, double mutant cycle analysis of
OmpA provided the ﬁrst evidence that clustering of aromatic resi-
dues provides a driving force for OMP folding and stability [177].
Analysis of OmpA folding into octyl maltoside micelles showed
that, although OmpA folding remained irreversible when urea was
used as a denaturant, reversibility could be obtained using GuHCl
as an alternative denaturant [156]. A full kinetic characterisation
of the folding mechanism was undertaken using chevron plot anal-
ysis and revealed that OmpA folds via a three-state mechanism to a
native-like protein that has a thermodynamic stability much high-
er than that measured in SUVs (DGoctylmaltoside  65.2 kJ/mol,
DGSUVs  14.2 kJ/mol) [156,172]. This result was conﬁrmed in a
subsequent study of OmpA folding into detergent micelles of
N-lauryl-N,N-dimethylammonium-N-oxide (LDAO, DGLDAO 
60 kJ/mol) [173]. By contrast, the thermodynamic stability of
OmpA in the amphipol A8-35 was found to be lower than that in
detergent SUVs (DGA8-35  8 kJ/mol), and the time taken to
reach equilibrium during (un)folding in A8-35 was reduced to
25 days, compared with 52 days in LDAO [173]. These studies dem-
onstrate the utility of different bilayer mimics to study membrane
protein stability and function, allowing kinetic reversibility on an
experimentally tractable timescale in vitro.
OmpA was also used in the ﬁrst in vitro studies of the effect of a
periplasmic chaperone on OMP folding into bilayers. Skp (Fig. 5b)
was shown to maintain unfolded OmpA in a soluble state at low
urea concentrations (0.4 M), to accelerate OmpA folding into neg-
atively charged SUVs, but to retard folding into zwitterionic SUVs
[180]. Additionally, pre-binding of the Skp:OmpA complex to LPS
prior to addition of lipid was shown to promote folding into either
negatively charged or zwitterionic SUVs suggesting that LPS may
play a role in OMP assembly [180]. Incorporation of full length
BamA into liposomes was found to increase the folding rate
constant of the OmpA b-barrel domain into LUVs of diC12:0PC
[181]. The transmembrane domain of BamA alone gave a small,
twofold increase in the folding rate constant, which is comparable
to the rate increase when FomA, an OMP not implicated in OMP
assembly, is incorporated into the liposomes. This suggests that
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from non-speciﬁc perturbations of the local lipid environment
[181]. This study also showed that incorporation of 20% diC12:0PE
into the diC12:0PC LUVs has an inhibitory effect on OmpA folding
which was overcome by the incorporation of BamA into the lipo-
somes. These experiments suggest how OMPs may overcome the
barrier to folding in vivo by destabilisation of the OM, which is
composed of approximately 80% PE lipids, in the presence of BamA
[181]. Finally, the previously observed retardation of OmpA folding
into zwitterionic bilayers in the presence of Skp was shown to be
ablated in the presence of BamA. This is possibly mediated through
the interaction of negatively charged patches on the surface of the
POTRA domains with positively charged Skp [181,182]. Together,
the available data on OmpA folding has provided valuable insights
into the forces that govern the folding of OMPs. Lack of such exten-
sive data on other OMPs, however, makes general conclusions hard
to draw.
Comparative studies of OMP folding
The study of homologous proteins has been utilised widely in
the ﬁeld of protein folding [183,184]. Application of this approach
to water soluble proteins includes the homeodomain-like super-
family [16,185], a-spectrin domains [37,184,186–189], bacterial
immunity proteins [190–192], ribosomal S6 proteins [193,194]
and immunoglobulin-like domains [195–199]. These studies have
yielded valuable insights into the role of protein topology, amino
acid sequence and secondary structure propensity on folding
mechanisms [183,184]. Recently, Burgess et al. adopted a screening
approach using cold SDS–PAGE analysis to determine the folding
yield of nine different OMPs (OmpX, OmpW, OmpA, PagP, OmpT,
OmpLA, FadL, Omp85 (BamA) and OmpF) under different condi-
tions [200]. The effects of pH, temperature, vesicle size and lipid
composition were investigated, revealing that, in general, folding
yield was increased by using pH values of 8–10, lipids with shorter
acyl chains and smaller vesicle diameter [200]. These results ac-
cord with previous work on the effects of membrane thickness
and curvature on the folding of OmpA [170]. A single condition
to maximise the folding yield of all nine OMPs could not, however,
be identiﬁed [200].
High temperature has been reported to increase the folding
yield of OmpA [169,201], FomA [202] and OmpX [201], but increas-
ing temperature had varying effects on the folding yield of the
OMPs in the Burgess study [200]. This variation was proposed to
arise from the different aggregation propensities of the OMPs stud-
ied at higher temperature [200]. The aggregation propensity of the
nine OMPs in the urea-unfolded state was investigating using sed-
imentation velocity analytical ultra-centrifugation, revealing that
self-association did not correlate well with folding efﬁciency
[203]. Some trends were observed, however, showing that addition
of salt (50–400 mM) and lower pH (values 6–7) increase self-asso-
ciation, while the presence of P4 M urea kept all the OMPs in a
monomeric state [203]. The relatively low aggregation propensity
of OmpA has since been attributed to the presence of the periplas-
mic domain, which has been shown to fold independently of the b-
barrel domain [204]. A thorough screen to establish conditions for
optimal folding of OmpLA was then conducted using the results of
previous studies as a guide [200,203], revealing that OmpLA folds
reversibly into LUVs diC12:0PC at pH 3.8, 37 C [165]. These condi-
tions also allowed reversible folding of PagP and OmpW, but not
the other OMPs studied [108]. The difﬁculty in ﬁnding conditions
suitable for the folding of different OMPs is thus a challenge, mak-
ing comparative studies of these homologous proteins challenging.
It is therefore difﬁcult to draw out similarities and differences in
the folding mechanism of a single protein class in the context of
OMP folding mechanisms.PagP
PagP is an OMP from E. coli that forms an 8-stranded b-barrel
with a 19-residue amphipathic a-helix at its N-terminus (Fig. 2d)
[205–207]. The b-barrel is tilted by approximately 25 to the mem-
brane normal [205,206,208], stabilised in this position by the inter-
actions of the aromatic girdles with the membrane intrafacial
region [209]. PagP is a palmitoyl transferase enzyme, which trans-
fers a palmitate chain from a phospholipid to hexa-acylated lipid A
and thus helps to reinforce the structure of the outer membrane
[210]. Folding studies on a C-terminally His-tagged construct of
PagP (HT PagP) revealed that the protein folds into both detergent
micelles and liposomes in vitro [211]. Unlike OmpA, a high concen-
tration of urea (7 M) was required to solubilise the protein and pre-
vent aggregation prior to insertion [143,211]. Far-UV CD was used
to follow the formation both b-sheet structure and tertiary struc-
ture (via a Cotton effect between tyrosine-26 and tryptophan-66)
[211,212]. In accordance with previous results on OmpA, second-
ary and tertiary structure were found to form concomitantly dur-
ing HT PagP folding into either cyclofos-7 micelles or diC12:0PC
liposomes (SUVs and LUVs) [170]. Mutants of HT PagP were then
created to investigate the role of the N-terminal a-helix (residues
1–19) in folding, since the possession of a periplasmic a-helix is
an unusual feature of an OMP [211]. This study demonstrated that
the helix increases the stability of folded HT PagP in liposomes, but
this effect was not so pronounced in detergent, illustrating the
importance of the lipid bilayer in the stability of the native state
and the importance of developing membrane-like mimics for stud-
ies of OMP stability [211]. One mutant in which a conserved resi-
due in the a-helix, tryptophan-17, was replaced with alanine,
unfolded ﬁfty times more rapidly that the wild-type [211].
Moreover, in a HT PagP helix deletion construct, mutation of argi-
nine-59, located in the intrafacial region of the b-barrel domain, to
tryptophan restored the folding and unfolding kinetics in lipo-
somes to rates similar to those of the wild type protein, demon-
strating the importance of the aromatic girdle in the folding and
stability of PagP [213].
By systematically varying the protein concentration and study-
ing the folding of HT PagP under a range of lipid-to-protein ratios
(LPRs), conditions were established under which the HT PagP
unfolding transition is completely reversible in diC12:0PC LUVs
[157]. Equilibrium stability studies and kinetic chevron plot analy-
sis of HT PagP (un)folding revealed that the protein folds via a two-
state mechanism over the range of urea concentrations studied
(7.8–10 M). A U-value analysis was then undertaken for HT PagP
using point mutants of 19 residues spread throughout the protein
structure [157]. These experiments provided the ﬁrst insights into
the structural features of a transition state for OMP folding, sug-
gesting a polarised transition state in which the N-terminal half
of the protein remains largely unstructured, whilst the C-terminal
half of the protein is native-like (Fig. 9) [157]. Interestingly, two
negative U-values were observed, providing evidence for stabilisa-
tion of the transition state by non-native interactions [157]. The
resulting mechanism of tilted insertion is consistent with the con-
certed folding and insertion suggested for OmpA [143,144,170]. It
remains to be seen whether this mechanism is observed for other
OMPs.
Kinetic analysis of HT PagP (un)folding over a range of urea con-
centrations (7.8–10 M) revealed that folding into diC12:0PC LUVs is
best described by a burst phase followed by a single exponential
phase [157,211,214]. Lowering the lipid-to-protein ratio, the HT
PagP concentration, or inclusion of diC12:0PE in the diC12:0PC LUVs,
resulted in a burst phase followed by two exponential phases
[214]. Interrupted refolding experiments, in which folding is
allowed to proceed for varying lengths of time before unfolding
is re-initiated by dilution into high urea concentrations, were also
Fig. 9. U-Value analysis of HT PagP. UF-values determined from kinetic analysis of HT PagP variants are mapped onto a ribbon diagram (left) and a topology model (right).
Regions withUF-values close to 0 are shown in red, regions withUF-values close to 1 are shown in blue, intermediateUF-values are shown in purple,UF-values less than 1 are
shown in orange and undetermined UF-values are grey. Reproduced with permission from [157].
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of the native state is best described by two rate constants indica-
tive of parallel folding pathways [214], a feature also seen in the
folding of some water-soluble proteins [145,197,215–218]. Since
the unfolding kinetics of HT PagP are well described by single
exponential kinetics under all conditions tested, there was insufﬁ-
cient evidence for an alternative native-like state of HT PagP [214].
The slower pathway most likely arises from a second population of
folding-competent HT PagP molecules in solution ready to adsorb
onto the lipid upon exposure of free membrane surface [214].
More recently, kinetic analysis of an untagged variant of PagP
has been undertaken in the presence of SurA and Skp [92]. This
PagP construct, initially reported by Burgess et al. [200], was cho-
sen for folding assays in the presence of soluble chaperones as it
had been reported to be folding competent in urea concentrations
as low as 1 M, in stark contrast with the high urea concentrations
required for efﬁcient folding of HT PagP [200,211]. Interestingly,
however, folding of PagP is not fully reversible under conditions
which promote reversible folding of HT PagP, again highlighting
the difﬁculty in generating OMPs suitable for equilibrium denatur-
ation studies [92]. Nonetheless, the folding kinetics of PagP into
both zwitterionic and negatively charged liposomes were investi-
gated in the presence and absence of Skp or SurA (Fig. 10) [92].
These experiments showed that membrane composition and ionicFig. 10. Schematic of the effects of Skp and SurA on the refolding of PagP. SurA and P
interacts with PagP, retarding the PagP folding rate into zwitterionic liposomes, but ac
dependent on the ionic strength of the buffer. Additionally, the holdase activity of Skp w
PagP under conditions which strongly favour aggregation of this construct. This ﬁgure wstrength of the buffer strongly inﬂuences the effect that Skp has on
PagP folding, suggesting that electrostatic interactions play an
important role in the mechanism of action of this chaperone
[92], consistent with the previous results on Skp-mediated folding
of OmpA [92,182]. SurA, however, did not affect the observed fold-
ing rates of PagP, in contrast with the results observed for OmpT
refolding [135], but consistent with the view that Skp and SurA
may act by distinct mechanisms in partially redundant chaperone
pathways [78,105]. The ability of Skp to prevent the aggregation of
HT PagP was also investigated, revealing that even under condi-
tions in which aggregation is strongly favoured, Skp can rescue
the folding and membrane insertion of HT PagP [92]. Together,
these studies indicate the power of combining different methods
to study the folding mechanism of an OMP and set the scope for fu-
ture investigations into how OMPs fold both unassisted and as-
sisted by folding factors in vitro and in vivo.
Summary and outlook
Early experiments on the folding of water-soluble proteins fo-
cused on small, single domain proteins as these provide relatively
simple folding models [3,11,13,14]. In the intervening decades,
many details on the folding of these proteins have been elucidated
as new experimental methods and computational techniques haveagP do not interact stably under the conditions of the refolding assay. Skp readily
celerating the folding rate of PagP into negatively charged liposomes in a manner
as demonstrated by its ability to rescue the folding and membrane insertion of HT
as adapted from [92] with permission from Elsevier,  2013.
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beginning to be investigated experimentally, including studies of
multidomain proteins, oligomeric proteins, folding in the presence
of chaperones and in the cellular milieu [40,41,139,219]. Even ﬁfty
years after Anﬁnsen’s experiments, the ﬁrst simulations of protein
folding in all-atom detail have only been reported in the last two
years and these initial studies were limited to small (<100 resi-
dues), single domain proteins [30,220,221]. More recently, the
characterisation of the folding and assembly of a dimeric protein
in atomistic detail using equilibrium MD simulations has paved
the way for simulation studies of the folding of oligomeric proteins
[222]. Application of simulation techniques to study integral mem-
brane proteins ﬁrstly requires the protein under study to be cor-
rectly positioned within the bilayer as this information is not
obtained when membrane protein structures are determined by
X-ray crystallography or NMR [223]. This is often achieved by ﬁrst
applying a coarse-grained approach to correctly position the pro-
tein within the membrane and using these results to guide atom-
istic simulations to obtain detailed information on lipid-protein
interactions and protein dynamics [223]. The multiscale simula-
tion approach has been successful in probing the lipid interactions
of aquaporins, ion channels and G-protein coupled receptors,
among others, but simulating the complexities of lipid organisation
within membranes remains a challenge in this ﬁeld [223,224].
Similar to the evolution of studies of water-soluble protein
folding, analysis of OMP folding mechanisms, thus far, have fo-
cused on a small subset of relatively simple proteins that are ame-
nable to the array of kinetic and thermodynamic assays required to
determine folding mechanisms [58,159]. Recent trends, however,
suggest that the ﬁeld of membrane protein folding is already pro-
gressing towards more complex folding systems. Folding models
utilised thus far include OmpA and Omp85 (a BamA homologue)
both of which have soluble, periplasmic domains, the trimeric por-
in, OmpF and the large, 19-stranded hVDAC [108,200,203,225].
Moreover, the use of periplasmic chaperones to aid folding and
membrane insertion has now been applied to several different
folding systems [92,108,135,182].
Membrane protein folding is complicated by the need to recre-
ate a suitable membrane mimetic environment in vitro into which
the protein can fold [47]. While early studies concentrated on sim-
ple micellar systems, these often do not provide a good mimic for
the complex, heterogeneous environment of a membrane in vivo
and can lead to inactivation or aggregation of the protein of inter-
est [226]. The use of lipid-based mimics, usually synthetic lipo-
somes, has provided a wealth of information based on the ability
to introduce guest lipids to modulate surface charge, lateral pres-
sure and membrane ﬂuidity and to examine their effect on OMP
folding and stability. Studies to date have focused on relatively
simple lipid mixtures, often with short acyl chains (C12), as these
have been shown to promote the folding of OMPs in vitro, and at
lipid-to-protein molar ratios (often 400:1 to 3200:1, or up to
approximately 100:1 by weight) which far exceed those encoun-
tered in biological membranes (in the range 1:1 to 1:3 by weight
[227]). While much has been learned about the interactions be-
tween OMPs and their surrounding lipid environment from these
studies, these simple mimics do not accurately represent the fold-
ing situation in vivo. Indeed, the membrane environment of OMPs
in vivo is characterised by variable lipid composition and asymmet-
ric distributions of lipids, as well as being densely packed with the
many proteins associated with, and inserted into, the bilayer [63].
As the experimental toolbox for the folding of OMPs continues
to expand, the level of complexity attainable in in vitro models is
likely to increase. Additionally, as the gap in understanding be-
tween the folding of OMPs and water-soluble proteins continues
to decrease, the similarities and differences between the folding
mechanisms of these two protein classes will emerge. Thisknowledge will be critical in understanding some of the fundamen-
tal biophysical questions which remain to be answered, such as the
relationship between the primary sequence of a protein and its
native structure in the context of water or lipid as the solvent,
and how chaperones assist folding in vitro and in vivo. Moreover,
these concepts will be critical in reﬁning current knowledge of pro-
tein folding mechanisms and working towards a universal folding
theory which encompasses all of nature’s proteins.
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